Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK’s Bexxar could oust lymphoma chemotherapy
Bexxar, a new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy and with fewer side effects, was evaluated in patients with
Bexxar, a new form of treatment for lymphoma that takes a fraction of the time of traditional chemotherapy and with fewer side effects, was evaluated in patients with
Carpal tunnel syndrome (CTS) is marked by numbness, weakness, and pain in the wrist, hand and arm, and occurs when the median nerve, which runs from the forearm
Neurofibromatosis frustrates doctors because there is currently no effective treatment. Now, however, researchers have identified a promising inflammatory cell target to treat the symptoms of neurofibromatosis. The researchers
Infasurf (calfactant) intratracheal suspension decreases the incidence of respiratory distress syndrome (RDS), mortality due to RDS, and air leaks associated with RDS. “We are pleased to add Infasurf
In January 2004, Myogen announced the initiation of patient enrollment in ARIES 1 and 2, two 186-patient trials in pulmonary arterial hypertension (PAH). ARIES-1 is currently being conducted
MedImmune may also receive certain milestone payments and royalties on future development and sales of an investigational vaccine co-developed by MedImmune and GSK for human papillomavirus (HPV), the
Xcyte withdrew its FDA submission of the clinical protocol for a planned phase II/III trial of Xcellerated T-cells in chronic lymphocytic leukemia, after the FDA requested further discussion
The study showed that Oral-lyn administered in a divided dose produces pharmacokinetic and glucodynamic profiles comparable to that produced by injected regular human insulin (administered in a divided
The Alliance for Lupus Research (ALR) is a leading source of private funding for lupus investigations and, since its inception in 1999, has committed more than $30 million
Kyorin and ActivX have been collaborating since May 2002 to discover new drugs for the treatment of type 2 diabetes. The collaboration was expanded in early 2004 to